ExodusPoint Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

ExodusPoint Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.8K	Buy	+14,029	New	+$69.2K	﹤0.01%	1469
2019 Q2	–	Sell	-515	Closed	-$41K	–	1266
2019 Q1	$41K	Buy	+515	New	+$33.2K	﹤0.01%	645

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ExodusPoint Capital Management's IMDX Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 14,029 shares worth $82.8K. The stake represents ﹤0.01% of the portfolio and ranks #1469 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in IMDX as recently as Q1 2019.

ExodusPoint Capital Management first reported a position in IMDX in Q1 2019 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

ExodusPoint Capital Management held 14,029 shares of Insight Molecular Diagnostics worth $82.8K as of Q2 2026.
Insight Molecular Diagnostics was a new ExodusPoint Capital Management position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1469 holding.
ExodusPoint Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2019 and has held it in 2 quarters since.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.